Hypercholesterolemia secondary targets: Difference between revisions
Jump to navigation
Jump to search
Kashish Goel (talk | contribs) No edit summary |
Kashish Goel (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
{{Hypercholesterolemia}} | {{Hypercholesterolemia}} | ||
'''Editor-In-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto:mgibson@perfuse.org] Phone:617-632-7753; '''Associate Editor(s)-In-Chief:''' [[Kashish Goel|Kashish Goel, M.D.]] | '''Editor-In-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto:mgibson@perfuse.org] Phone:617-632-7753; '''Associate Editor(s)-In-Chief:''' [[Kashish Goel|Kashish Goel, M.D.]] | ||
__NOTOC__ | |||
==The Metabolic Syndrome== | ==The Metabolic Syndrome== | ||
The [[metabolic syndrome]] is identified as a secondary target of therapy in the NCEP ATP III guidelines, beyond [[LDL]] cholesterol. The [[metabolic syndrome]] is a constellation of multiple risk factors which are lipid and non-lipid in origin. The basic abnormality associated with the [[metabolic syndrome]] is insulin resistance. | The [[metabolic syndrome]] is identified as a secondary target of therapy in the NCEP ATP III guidelines, beyond [[LDL]] cholesterol. The [[metabolic syndrome]] is a constellation of multiple risk factors which are lipid and non-lipid in origin. The basic abnormality associated with the [[metabolic syndrome]] is insulin resistance. | ||
==Non-HDL== | |||
Revision as of 14:50, 15 September 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753; Associate Editor(s)-In-Chief: Kashish Goel, M.D.
The Metabolic Syndrome
The metabolic syndrome is identified as a secondary target of therapy in the NCEP ATP III guidelines, beyond LDL cholesterol. The metabolic syndrome is a constellation of multiple risk factors which are lipid and non-lipid in origin. The basic abnormality associated with the metabolic syndrome is insulin resistance.